Last reviewed · How we verify

Calcium hydroxylapatite

DeNova Research · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Calcium hydroxylapatite is a Small molecule drug developed by DeNova Research. It is currently FDA-approved. Also known as: Radiesse, CaHA.

Calcium hydroxylapatite is a naturally occurring mineral form of apatite with the formula Ca5(PO4)3(OH), used in medical interventions such as lateral sinus floor augmentation and skin laxity treatment. It is classified as a small molecule modality, with synonyms including calcium chloride and calcium chloride anhydrous.

At a glance

Generic nameCalcium hydroxylapatite
Also known asRadiesse, CaHA
SponsorDeNova Research
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Calcium hydroxylapatite

What is Calcium hydroxylapatite?

Calcium hydroxylapatite is a Small molecule drug developed by DeNova Research.

Who makes Calcium hydroxylapatite?

Calcium hydroxylapatite is developed and marketed by DeNova Research (see full DeNova Research pipeline at /company/denova-research).

Is Calcium hydroxylapatite also known as anything else?

Calcium hydroxylapatite is also known as Radiesse, CaHA.

What development phase is Calcium hydroxylapatite in?

Calcium hydroxylapatite is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing